Trial Profile

Efficacy and safety of combination of anlotinib and etoposide in the maintenance treatment of extensive small cell lung cancer: a single-arm, prospective, phase II trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Etoposide (Primary) ; Carboplatin; Cisplatin
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

14 Oct 2023 Status changed from recruiting to completed.
14 Oct 2023 Results assessing effectiveness of anlotinib plus etoposide for maintenance therapy in ES-SCLC, published in the Investigational New Drugs.
07 Jun 2022 Updated Results (At data cut-off January 7, 2022, n=20 ) presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com